2021-2025 Spain Hospital Cancer Diagnostics Market: Supplier Shares by Test, Volume and Sales Segment Forecasts for Major Tumor Markers, Competitive Landscape, Innovative Technologies, Instrumentation Review, Opportunities for Suppliers

October 2021 | 521 pages | ID: 2903D4A1E66EEN
Venture Planning Group

Abstracts

This new report from LeadingMarketResearch.com contains 521 pages and 41 tables.

The report is available by section, and can be customized to specific information needs and budget.

The report presents a comprehensive analysis of the Spanish hospital cancer diagnostics market, including:

• Major issues pertaining to the Spanish hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.;
• Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
• Test volume and sales forecasts for 40 cancer diagnostic procedures performed in Spanish hospitals. ;
• Current instrumentation technologies and feature comparison of leading analyzers.;
• Sales and market shares of & leading suppliers.;
• Emerging diagnostic technologies and their potential market applications.;
• Product development opportunities.;
• Profiles of current and emerging suppliers, including their sales, market shares, product portfolios,& marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.;
• Business opportunities and strategic recommendations for suppliers.

Contains 521 pages and 41 tables

Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VII. WORLDWIDE @MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology
  1. Breast Cancer
  2. Lung Cancer
  3. Colon and Rectum Cancer
  4. Prostate Cancer
  5. Stomach Cancer
  6. Leukemia
  7. Lymphoma
  8. Oral Cancer
  9. Skin Cancer
  10. Uterine Cancer
  11. Ovarian Cancer
  12. Bladder Cancer
B. Major Current and Emerging Cancer Diagnostic Tests
  1. Introduction
  2. Tumor Marker Classification
  3. ACTH
  4. Alpha-Fetoprotein (AFP)
  5. Beta-2 Microglobulin
  6. CA 15-3/27.29
  7. CA 19-9
  8. CA-125
  9. Calcitonin
  10. Carcinoembrionic Antigen (CEA)
  11. Estrogen and Progesterone Receptors
  12. Ferritin
  13. Gastrin
  14. Human Chorionic Gonadotropin (HCG)
  15. Insulin
  16. NSE
  17. Occult Blood
  18. PAP Smear/HPV
  19. Prostatic Acid Phosphatase (PAP)
  20. Prostate-Specific Antigen (PSA)
  21. Squamous Cell Carcinoma Antigen (SCC)
  22. T and B Lymphocytes
  23. TdT
  24. Thyroglobulin
  25. Tissue Polypeptide Antigen (TPA)
  26. Biochemical Tumor Markers
  27. Oncogenes
    Abl/abl-bcr
    AIB1
    BCL-2
    BRCA1
    CD44
    C-fos
    C-myb
    C-myc
    CYP-17
    Erb-B
    HPC1
    N-myc
    P40
    P51
    P53
    PIK3CA
    PTI-1
    Ras
    Reg
    Sis
    Src and others
  28. Polypeptide Growth Factors
    Basic Fibroblast Growth Factor
    Beta-TGF
    Cachectin (TNT)
    Calmodulin
    ECFR
    Nerve Growth Factor (NGF)
    Epidermal Growth Factor (EGF)
    Ornithine Decarboxylase
    Transferrin
    Transforming Growth Factor-Alpha
  29. Ectopic Hormones
  30. Colony Stimulating Factors
  31. Lymphokines
    Alpha-Interferon
    B Cell Growth Factors
    B Cell Growth Factor (BCGF)
    Gamma-Interferon
    Interleukin-1 (IL-1)
    Macrophage Activating Factor
  32. Immunohistochemical Stains
  33. Emerging Tumor Markers
    N-Acetylglucosamine
    Actin
    Alpha-Actin
    Antineuronal Antibodies
    7B2
    B  72.3
    Bax
    BCD-F9
    BLCA-4
    Blood Group Antigens A,B,H
    CA
    CA 72-4/TAG-72
    CA
    CA-242
    CA-549
    CAM
    CAR-3
    Cathepsin-D
    Chromogranin A and B
    Cluster 1 Antigen
    Cluster-5/5A Antigen
    CTA
    CU18
    DR-70
    DU-PAN-2
    Endometrial Bleeding Associated Factor
    Endostatin
    Epithelial Membrane Antigen
    Feulgen Hydrolysis
    Fibronectin
    FSH
    (1->3)-L-fucosyltransferase
    Gastrin-Releasing Peptide (GRP)
    GDCFP-15
    Glucagon
    Glycoamines
    H23
    Her-2
    Human Carcinoma Antigen
    HPA
    HSP27
    Intermediate Filaments
    Cytokeratins/CK18/Cyfra 21-1
    Desmin
    Gliofibrillary Acid Protein
    Neurofilaments
    Vimentin
    KA
    Kinases
    KP16D3
    LAI
    Leukocyte Common Antigen
    Lewis Antigens
    Lysophosphatidic Acid (LPA)
    Ma 695/Ma
    MABDF3
    MAG
    ME1
    Minactivin
    MN/CA9
    MSA
    Mucin Cancer Antigen (MCA)
    Multiple Tumor Suppressor
    Myosin
    NEA-130
    NMP22
    OA-519
    Opioid Peptides
    P-glycoprotein
    Pancreatic Oncofetal Antigen (POA)
    Placental Lactogen
    PR92
    Proliferative Index, Ki-67
    Px
    RB Inactivation/Deletion
    Ret
    SCCL
    Selectin
    Sialic Acid
    Sialyl SSEA-1/SLX
    SN10
    Somatostatin
    TA-90
    TABA
    Tachykinin
    TAG
    TPS
    Troponin
    Tubulin
    VCAM
    VEGF
    Villen and others
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
  3. Molecular Diagnostics
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies
E. Personal Testing

VIII. COUNTRY ANALYSIS

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Dynamics, Trends, Size and Growth
  Volume Forecasts by Test and Market Segment
  Sales Forecasts by Test and Market Segment
  Major Supplier Sales and Market Shares

IX. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
Hologic
Leica Biosystems
Ortho-Clinical Diagnostics
PerkinElmer
Qiagen
Roche
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako and others.